cagrisema cagrilintide semaglutide phase 3 2025 Incretin-based therapies for the treatment of obesity-related diseases A stronger Ozempic is coming.

A 2026 biopharmaceutical review in a journal I do not trust said there is no identified high-affinity receptor, no validated molecular target, and a wide disconnect between the tidy preclinical effects and any coherent pharmacology

Building trust requires radical transparency about what is known, what is inferred, and what remains unknown

Men who cannot tolerate the gastrointestinal effects of semaglutide or tirzepatide may find cagrilintide more manageable as a standalone option

Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes

Our study showed that co-administration of OIFE can restore the population of immature neurons in the SGZ

S2CID 58655082